Takahashi S, Igarashi H, Ishiyama N, Nakamura K, Masubuchi N, Ozaki M, Saito S, Aoyagi T, Itoh T, Hirata I
Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.
Zentralbl Bakteriol. 1993 Sep;280(1-2):144-9. doi: 10.1016/s0934-8840(11)80950-3.
The aim of this study is to clarify the relationship between Helicobacter pylori (H. pylori) infection and gastric carcinoma. 94 patients with gastric carcinoma and 111 patients with chronic gastritis were involved in this study. They were classified into 3 age groups: Group A (40 years and under), Group B (41-59), Group C (60 years and over). Serum samples were tested for H. pylori IgG antibodies by ELISA and for pepsinogen (PG) by RIA. The ratio of PG I/PG II was used as a marker for atrophic gastritis. Results were as follows. In the incidence of H. pylori antibodies, there was no significant differences between gastric carcinoma and chronic gastritis in any of the groups. In the quantity of H. pylori antibodies, there was no significant difference between gastric carcinoma and chronic gastritis in any of the groups. The ratio of PG I/PG II was significantly decreased in H. pylori positive cases when compared to H. pylori negative cases in each group with chronic gastritis and group A and B with gastric carcinoma. The ratio of PG I/PG II in gastric carcinoma was significantly lower than that of chronic gastritis. As conclusion, from the point of view of the prevalence of H. pylori, it is suggested that H. pylori is not a direct causal agent in the pathogenesis of gastric carcinoma.
本研究旨在阐明幽门螺杆菌（H. pylori）感染与胃癌之间的关系。本研究纳入了94例胃癌患者和111例慢性胃炎患者。他们被分为3个年龄组：A组（40岁及以下）、B组（41 - 59岁）、C组（60岁及以上）。通过酶联免疫吸附测定（ELISA）检测血清样本中的幽门螺杆菌IgG抗体，并通过放射免疫分析（RIA）检测胃蛋白酶原（PG）。PG I/PG II的比值被用作萎缩性胃炎的标志物。结果如下。在幽门螺杆菌抗体的发生率方面，任何一个年龄组的胃癌患者和慢性胃炎患者之间均无显著差异。在幽门螺杆菌抗体的数量方面，任何一个年龄组的胃癌患者和慢性胃炎患者之间也无显著差异。在每组慢性胃炎患者以及A组和B组胃癌患者中，幽门螺杆菌阳性病例的PG I/PG II比值与幽门螺杆菌阴性病例相比显著降低。胃癌患者的PG I/PG II比值显著低于慢性胃炎患者。结论是，从幽门螺杆菌的流行情况来看，提示幽门螺杆菌不是胃癌发病机制中的直接致病因素。
